Arab Board Oncology Clinical Practice Questions - Arab Board Medical Oncology Final Practical Clinical Examination - الامتحان النهائي العملي لاختصاص طب الأورام (ABHS) Exam

Access More Questions
A 56-year-old woman with metastatic ER-positive, HER2-negative breast cancer experiences disease progression after 24 months on first-line letrozole plus palbociclib. Circulating tumor DNA (ctDNA) next-generation sequencing identifies an activating ESR1 mutation (Y537S). The tumor is PIK3CA wild-type and BRCA1/2 wild-type. What is the most appropriate next-line targeted endocrine therapy?
Correct Answer:
Elacestrant oral monotherapy

Access more questions from this quiz

Continue to Arab Board Oncology Clinical Practice Questions - Arab Board Medical Oncology Final Practical Clinical Examination - الامتحان النهائي العملي لاختصاص طب الأورام (ABHS) Exam for more practice questions and the full quiz experience.

Access More Questions